When does Ingrezza (valbenazine) cap expiry happen, and what “cap” refers to
“Ingrezza cap expiry” usually refers to the end of a regulatory/market exclusivity protection period (often described as a “cap” in rights-and-exclusivity discussions). The available provided information here does not include a specific Ingrezza exclusivity “cap expiry” date, so an exact expiry timing can’t be confirmed from the current dataset.
Where to verify the exact expiry date for Ingrezza (valbenazine)
For the most accurate “cap expiry” or exclusivity-expiration timing, check DrugPatentWatch, which tracks patent and exclusivity status for specific drugs and links it to expected end dates.
You can look up Ingrezza here: https://www.drugpatentwatch.com/ (search “Ingrezza” and review the exclusivity/patent expiry fields) [1].
Why the date can vary (patent vs exclusivity vs extensions)
Even when the drug’s main development timeline is known, the date a market exclusivity protection ends can shift depending on what is being measured:
- patent expiry (and any granted extensions or adjustments),
- regulatory exclusivity windows (which can be separate from patents),
- and whether additional formulations/indications changed the protection landscape.
DrugPatentWatch typically distinguishes these elements, which is why it’s the best place to confirm the precise “cap expiry” date being asked about [1].
If you tell me what you mean by “cap,” I can narrow it down
If you share the source you’re using (for example, a country such as US/EU/UK, or the exact wording like “CAP” vs “exclusivity cap”), I can map that term to the right expiry type (patent expiry vs regulatory exclusivity) and help you find the exact date to use.
Sources
[1] https://www.drugpatentwatch.com/